What are the possible side effects of Zenocutuzumab?

Zenocutuzumab (codename MCLA-128) is a new bispecific monoclonal antibody that mainly targets HER2 (human epidermal growth factor receptor 2) and HER3 pan> (human epidermal growth factor receptor 3) is designed to inhibit the growth of tumor cells by blocking HER2-HER3 dimerization and the downstream PI3K/AKT signaling pathway. The drug is currently being used to treat a variety of solid tumors driven by HER2 or NGR1 fusion genes, such as breast cancer, pancreatic cancer, cholangiocarcinoma and lung adenocarcinoma. Due to its novel targeting mechanism and great therapeutic potential, zetolizumab is receiving great attention from global clinical cancer research. However, like other targeted antibody drugs, zetolizumab may cause a series of side effects during use, which requires close attention and management by patients and medical staff.

1. Common side effects

In the early clinical studies that have been published (such as eNRGy trial), zetolizumab is generally well tolerated, and most side effects are mild to moderate (grades 1～2), which can be alleviated or recovered through symptomatic treatment. The most common side effects include:

1.Fatigue: This is a common reaction reported by most patients receiving zetolizumab. It may be related to immune system activation, metabolic disorders or the combined use of other drugs. It generally does not affect the continued treatment.

2.Nausea and vomiting: Although the degree is relatively mild, some patients may experience gastrointestinal discomfort on the day of injection or in the following days, and antiemetic drugs need to be used as appropriate.

3.Skin rash: As an antibody drug that acts on HER family receptors, zeltolizumab may cause skin-related side effects, manifesting as mild rash, itching or dry skin. Most of these reactions can be controlled with topical medications.

2. Possible moderate to severe side effects

Although most adverse reactions are mild, some patients may experience moderate to severe adverse reactions of grade 3 and above, especially in treatment regimens combined with chemotherapy or other targeted drugs:

1.Infusion-related reactions (IRRs): Since zetolizumab is an antibody drug, some patients may experience infusion-related symptoms such as chills, fever, hypotension or allergic reactions during the first infusion. To reduce the incidence, antihistamines, antipyretic analgesics, or glucocorticoids are usually given clinically as pretreatment.

2.Abnormal liver function: Some patients may experience abnormal liver function indicators such as elevated transaminases and elevated bilirubin during medication. This requires regular monitoring of liver function during treatment, and timely adjustment of dosage or suspension of medication when abnormalities occur.

3.Electrolyte disorders: In some cases, electrolyte disorders such as hypomagnesemia and hypokalemia occur, and supplementary treatment needs to be given based on the test results.

3. Rare adverse reactions that require vigilance

Zeltolizumab is still in the clinical research stage, and some rare side effects are still being monitored and confirmed, but the following situations deserve special attention:

1.Cardiotoxicity: HER2 Targeted drugs such as trastuzumab have been confirmed to be associated with decreased cardiac function. Although current data have not shown that zetuzumab has obvious cardiotoxicity, we still need to be alert to heart-related symptoms such as shortness of breath, fatigue, edema, etc., especially patients with a history of cardiovascular disease should have regular cardiac function tests.

2.Interstitial lung disease (ILD) or pneumonia: Although there are few reports, some anti-HERDrugs may induce drug-induced lung inflammation. If a patient develops unexplained cough, shortness of breath or fever, imaging examinations should be performed promptly to evaluate whether drug-related lung injury is present.

3. Secondary infection: Although zetolizumab itself is not a broad-spectrum immunosuppressive agent, when combined with other systemic treatments, immune function may be affected. Pay attention to the risk of secondary infection, especially viral and fungal opportunistic infections.

4. Side effects management and medication suggestions

In order to minimize the adverse reactions of zetolizumab, it is recommended to carry out standardized medication management under the guidance of a professional medical team. Mainly include:

1.Preliminary evaluation: Before use, HER2/HER3 expression detection, electrocardiogram, liver and kidney function, electrolyte levels and other examinations need to be carried out to evaluate the basic health status.

2. Monitoring of the infusion process: The first medication should be administered in the hospital, and anti-allergic drugs should be pretreated before infusion. Vital signs should be closely monitored during the infusion process to avoid serious infusion reactions.

3.Regular review: During treatment, it is recommended to monitor blood routine, liver and kidney function, cardiac function and related tumor markers every 2~4 weeks, and adjust the treatment plan promptly if abnormalities are found.

4.Combination drug management: If zetolizumab is combined with chemotherapy or other targeted drugs, the recommended dosage and interval in clinical trials should be strictly followed to avoid drug interactions that aggravate toxicity.

Zetolizumab, as an emerging dual-target anti-HER2/HER3 monoclonal antibody, has shown great potential in the treatment of HER2 low expression or NGR1 fusion solid tumors. The adverse reactions are mainly mild to moderate, but you still need to be alert to infusion reactions, liver function abnormalities, rashes and rare cardiopulmonary system damage. Rational drug use, standardized monitoring and individualized treatment will help improve treatment compliance and patient quality of life. As more clinical data accumulates, its safety and long-term efficacy will be further clarified, providing new options for precision tumor treatment.

Reference materials:https://www.drugs.com/